-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chronic lymphocytic leukemia (CLL) is a common malignant tumor of the blood system, with around 3,750 newly confirmed cases in the UK each year.
CLL is characterized by significant clinical and biological heterogeneity, with some patients suffering from stable asymptomatic diseases that do not require treatment, while others exhibit aggressive diseases with reduced survival.
's highly effective chemotherapy immunotherapy is currently a treatment strategy for patients with symptoms of CLL, the emergence of B-cell-like signaling path-pathens inhibitors (BCRi) and drugs targeting anti-apoptosis proteins, and the emergence of highly effective combination therapy options for both may improve the prognosis of patients.
increase in the regional association of progressive CLL-related bits and the increased rate of CLL among first-level relatives of patients with chain imbalance graphs is also a factor in the genetic susceptivity of the disease, as confirmed by the large-scale genome-wide association study (GWAS).
given the important genetic contribution to CLL susceptivity, the researchers hypothesically assume that inherent genetic mutations affect the development of the disease and are important for the prognosis of patients.
map and survival curve researchers at
progressive CLL-related endpoints identified two genomic endpoints related to diagnosis to treatment time from aggregate data from seven studies involving 842 cases, including 10q26.13 (rs736456) and 6p (rs3778076), which are powerful prognostic indicators for early CLL patients.
of nucleotytes of gene expression identified hypothetical functional genes associated with regulating the B-cell subject or congenital immune response, a key pathway to the onset of CLL.
All in all, the results of the study reveal that rs736456 and rs3778076 are prognostic indicators of CLL, and that the results also indicate that the development of the disease is determined by inherent genetic mutations and known somtic cell drivers.
